MMP9 and neoplasm: “Basal-like” subtype presents KRASG12D mutation, while “activated” stroma subtype expresses SPARC, WNT family members WNT2 and WNT5A, gelatinase B (MMP9), stromelysin 3 (MMP11), and FAP that contribute to tumor development [60].